Sanofi licenses worldwide rights on regenerative treatment for osteoarthritis and cartilage disorders from Scil Technology
23-Dec-2011
- Germany
The cartilage regenerative program is Scil Technology’s second program which has been out-licensed successfully. The first (GDF-5) was taken over by Medtronic after completion of Phase II.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.